Gland Pharma Limited specializes in the production of sterile injectable formulations, including vials, ampoules, pre-filled syringes, and lyophilized products. The company’s focus on sterile injectables positions it as a key player in critical care, oncology, ophthalmology, and other therapeutic areas. Gland Pharma’s state-of-the-art manufacturing facilities adhere to international quality standards, ensuring the production of high-quality and safe pharmaceutical products.
- Gland Pharma Limited reported Total Income for Q4 FY23 of ₹823.95 Crore down from ₹1,168.24 Crore year on year, a decline of 29.5%.
- Total Expenses for Q4 FY23 of ₹656.33 Crore down from ₹787.76 Crore year on year, a decline of 16.7%.
- Consolidated Net Profit of ₹78.68 Crore, down 72.5% from ₹285.90 Crore in the same quarter of the previous year.
- The Earnings per Share is ₹4.78, from ₹17.36 in the same quarter of the previous year.
Cochin Shipyard Limited (NSE:COCHINSHIP) Q4 FY22 Earnings Concall dated May. 26, 2022 Corporate Participants: Madhu S Nair -- Chairman & Managing Director Jose V J -- Director Finance Analysts: Vastupal Shah
Can you guess the name of the company that was listed during the IPO frenzy in 2020 and is the second largest player in the Indian municipal waste management industry?
“Hey, how is the market doing today?” “Oh!, its falling tremendously since morning” I am sure news like these might be a common topic of discussion for you nowadays. Interestingly,